Advances in tuberculosis diagnostics: The Xpert MTB/RIF assay and future prospects for a point-of-care test

The Lancet Infectious Diseases

Volumn 13, Issue 4, 2013, Pages 349-361

  Lawn, Stephen D ^a,b   Mwaba, Peter ^c,d   Bates, Matthew ^c,e   Piatek, Amy ^f   Alexander, Heather ^g   Marais, Ben J ^h   Cuevas, Luis E ⁱ   McHugh, Timothy D ^e   Zijenah, Lynn ^j   Kapata, Nathan ^c,d   Abubakar, Ibrahim ^e,k   McNerney, Ruth ^a   Hoelscher, Michael ^l   Memish, Ziad A ^m,n   Migliori, Giovanni Battista ^o   Kim, Peter ^p   Maeurer, Markus ^q   Schito, Marco ^p   Zumla, Alimuddin ^c,e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d MINISTRY OF HEALTH   (Zambia)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^j UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^k PUBLIC HEALTH ENGLAND   (United Kingdom)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m MINISTRY OF HEALTH   (Saudi Arabia)

ⁿ ALFAISAL UNIVERSITY   (Saudi Arabia)

^o IRCCS   (Italy)

^p NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^q KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENDEMIC DISEASE; EXTRAPULMONARY TUBERCULOSIS; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; SCIENTIFIC LITERATURE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; HEALTH CARE COSTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RIFAMPIN; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH;

EID: 84875602728     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70008-2     Document Type: Review

References (94)

1. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva, Switzerland.
2. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009, 68:2240-2246.
3. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
4. Tuberculosis diagnostics technology landscape report UNITAID, (accessed Dec 23, 2012). http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-Tuberculosis-Landscape_2012.pdf.
5. TB diagnostics and laboratory strengthening-WHO policy: definition of a new sputum smear-positive TB case, 2007 2007, WHO, World Health Organization, Geneva, Switzerland.
6. TB diagnostics and laboratory strengthening-WHO policy: reduction in the number of smears for the diagnosis of pulmonary TB, 2007 2007, WHO, World Health Organization, Geneva, Switzerland.
7. Same-day diagnosis of tuberculosis by microscopy: WHO policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
8. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
9. TB diagnostics and laboratory strengthening-WHO policy: the use of liquid medium for culture and DST, 2007 2007, WHO, World Health Organization, Geneva, Switzerland.
10. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
11. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement, June 27, 2008 2008, WHO, World Health Organization, Geneva, Switzerland.
12. Commercial serodiagnostic tests of diagnosis of tuberculosis: policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
13. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
14. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system: policy statement 2011, WHO, World Health Organization, Geneva, Switzerland.
15. Tuberculosis diagnostics: automated DNA test 2010, WHO, World Health Organization, Geneva, Switzerland.
16. Ulrich MP, Christensen DR, Coyne SR, et al. Evaluation of the Cepheid GeneXpert system for detecting Bacillus anthracis. J Appl Microbiol 2006, 100:1011-1016.
17. Lawn SD, Nicol MP Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011, 6:1067-1082.
18. Musser JM Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995, 8:496-514.
19. Sreevatsan S, Pan X, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997, 94:9869-9874.
20. Tyagi S, Kramer FR Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996, 14:303-308.
21. Tyagi S, Bratu DP, Kramer FR Multicolor molecular beacons for allele discrimination. Nat Biotechnol 1998, 16:49-53.
22. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
23. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert(R) MTB/RIF assay. J Clin Microbiol 2010, 48:2495-2501.
24. Banada PP, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010, 48:3551-3557.
25. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 161:1376-1395. American Thoracic Society.
26. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012, 64:580-588.
27. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
28. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
29. Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis 1994, 170:713-716.
30. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J 2012, 39:1269-1271.
31. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011, 49:1772-1776.
32. Causse M, Ruiz P, Juan Bautista GA, Casal M Comparison of two molecular methods for the rapid diagnosis of extrapulmonary tuberculosis. J Clin Microbiol 2011, 49:3065-3067.
33. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol 2011, 49:4341-4342.
34. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 2011, 49:1202-1205.
35. Ligthelm LJ, Nicol MP, Hoek KG, et al. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol 2011, 49:3967-3970.
36. Moure R, Martin R, Alcaide F Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol 2012, 50:513-515.
37. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C Xpert MTB/RIF, a new pillar in the diagnosis of extrapulmonary tuberculosis?. J Clin Microbiol 2011, 49:2540-2545.
38. Zeka AN, Tasbakan S, Cavusoglu C Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J Clin Microbiol 2011, 49:4138-4141.
39. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012, 40:442-447.
40. Lawn SD, Kerkhoff AD, Vogt M, Wood R High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr 2012, 60:289-294.
41. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One 2012, 7:e39966.
42. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011, 11:819-824.
43. Rachow A, Clowes P, Saathoff E, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 2012, 54:1388-1396.
44. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012, 55:1088-1095.
45. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013, 13:36-42.
46. Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J 2012, 31:1316.
47. Reid MJA, Shah NS Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009, 9:173-184.
48. Lawn SD, Wood R Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011, 204(suppl 4):S1159-S1167.
49. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011, 184:132-140.
50. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011, 8:e1001061.
51. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011, 8:e1001067.
52. O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012, 55:1171-1178.
53. Balcells ME, Garcia P, Chanqueo L, et al. Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile. Int J Tuberc Lung Dis 2012, 16:1349-1353.
54. Carriquiry G, Otero L, Gonzalez-Lagos E, et al. A diagnostic accuracy study of Xpert(R)MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. PLoS One 2012, 7:e44626.
55. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012, 54:1071-1079.
56. Turnbull ER, Kancheya NG, Harris JB, Topp SM, Henostroza G, Reid SE A model of tuberculosis screening for pregnant women in resource-limited settings using Xpert MTB/RIF. J Pregnancy 2012, 2012:565049.
57. Ntinginya EN, Squire SB, Millington KA, et al. Performance of the Xpert(R) MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania. Int J Tuberc Lung Dis 2012, 16:1468-1470.
58. Dorman SE, Chihota VN, Lewis JJ, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One 2012, 7:e43307.
59. Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011, 49:1621-1623.
60. Van Rie A, Mellet K, John MA, et al. False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012, 16:206-208.
61. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2012, 74:207-209.
62. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how to' practical considerations 2011, WHO, World Health Organization, Geneva, Switzerland.
63. Kurbatova EV, Cavanaugh JS, Shah NS, et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012, 16:355-357.
64. Performance of Xpert MTB/RIF version G4 assay, Nov 30, 2011 Foundation for Innovative New Diagnostics (FIND), (accessed Dec 10, 2011). http://www.stoptb.org/wg/gli/assets/documents/map/findg4cartridge.pdf.
65. Stevens W. Analysis of needed interface between molecular diagnostic tests and conventional mycobacteriology. 43rd Union World Conference on Lung Health; Kuala Lumpur, Malaysia; Nov 13-17, 2012. Symposium 24.
66. Trebucq A, Enarson DA, Chiang CY, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis 2011, 15:1567-1572.
67. Evans CA GeneXpert-a game-changer for tuberculosis control?. PLoS Med 2011, 8:e1001064.
68. Negotiated prices for Xpert MTB/RIF and FIND country list, August 2012 Foundation for Innovative New Diagnostics (FIND), (accessed Sep 12, 2012). http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html.
69. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB, Dec 6, 2010 WHO, (accessed Dec 8, 2010). http://www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf.
70. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8:e1001120.
71. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012, 26:987-995.
72. Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012, 60:e1-e7.
73. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012, 7:e36966.
74. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 2012, 17:1142-1151.
75. Kirwan DE, Cardenas MK, Gilman RH Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?. Am J Trop Med Hyg 2012, 87:197-201.
76. Scott LE, Gous N, Cunningham BE, et al. Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa. J Clin Microbiol 2011, 49:4356-4360.
77. Lawn SD, Kerkhoff AD, Wood R Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 2012, 16:701.
78. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012, 102:805-807.
79. Mitarai S, Okumura M, Toyota E, et al. Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2011, 15:1211-1217.
80. Bearinger JP, Dugan LC, Baker BR, et al. Development and initial results of a low cost, disposable, point-of-care testing device for pathogen detection. IEEE Trans Biomed Eng 2011, 58:805-808.
81. Lawn SD, Kerkhoff AD, Vogt M, Wood R Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
82. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012, 40:1211-1220.
83. Lawn SD Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012, 12:103.
84. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011, 38:1398-1405.
85. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009, 52:145-151.
86. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009, 23:1875-1880.
87. Lawn SD, Kerkhoff AD, Vogt M, Wood R Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012, 26:1635-1643.
88. Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One 2012, 7:e32876.
89. McNerney R, Wondafrash BA, Amena K, Tesfaye A, McCash EM, Murray NJ Field test of a novel detection device for Mycobacterium tuberculosis antigen in cough. BMC Infect Dis 2010, 10:161.
90. Kolk A, Hoelscher M, Maboko L, et al. Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis. J Clin Microbiol 2010, 48:4235-4238.
91. Bruins M, Rahim Z, Bos A, et al. Diagnosis of active tuberculosis by e-nose analysis of exhaled air. Tuberculosis (Edinb) 2012, published online Nov 2, 2012. 10.1016/j.tube.2012.10.002.
92. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375:1920-1937.
93. McNerney R, Daley P Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011, 9:204-213.
94. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012, 205(suppl 2):S147-S158.